Rapt Therapeutics Inc

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

RAPT THERAPTICS (RAPT) delivered earnings and revenue surprises of -26.92% and -28.12%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

RAPT THERAPTICS (RAPT) Reports Q1 Loss, Misses Revenue Estimates

SOUTH SAN FRANCISCO, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2021.

RAPT Therapeutics Reports First Quarter 2021 Financial Results

RAPT THERAPTICS (RAPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RAPT THERAPTICS (RAPT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Investors need to pay close attention to RAPT Therapeutics (RAPT) stock based on the movements in the options market lately.

Do Options Traders Know Something About RAPT Therapeutics (RAPT) Stock We Don't?

RAPT THERAPTICS (RAPT) delivered earnings and revenue surprises of 3.70% and -36.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

RAPT THERAPTICS (RAPT) Reports Q4 Loss, Misses Revenue Estimates

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the fourth quarter and year ended December 31, 2020.

RAPT Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced several upcoming preclinical poster presentations at the American Association for Cancer Research annual meeting demonstrating promise and potential of its pipeline of anti-cancer agents.

RAPT Therapeutics to Report Promising Preclinical Studies Supporting its Pipeline of Immunotherapy Platforms at AACR

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present at the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 12:00 pm Eastern Time.

RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that a webcast of Brian Wong, M.D., Ph.D., President and CEO, and Rodney Young, CFO, participating in a fireside chat in conjunction with the Piper Sandler 32nd Annual Virtual Healthcare Conference will be available today at 10:00 a.m. ET. A replay of RAPT's fireside chat may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

RAPT Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent operational and business progress.

RAPT Therapeutics Reports Third Quarter 2020 Financial Results

-Evidence of Monotherapy and Combination Activity in Charged Tumor Types--Company Advances Several Cohorts into Phase 2 Expansions--Conference Call and Webcast to be Held at 8:30 a.m. ET Today-

RAPT Therapeutics Reports Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that the Company plans to present initial data from its Phase 1/2 clinical trial of FLX475 in patients with multiple cancer indications in a premarket press release and webcast on Monday, November 16, 2020.

RAPT Therapeutics to Announce Initial Data from Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020 at 4:00 p.m. ET.

RAPT Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the addition of preeminent oncology thought leaders, Lisa Butterfield, Ph.D. and Lawrence Fong, M.D., to its Scientific Advisory Board.

RAPT Therapeutics Appoints Lisa Butterfield, Ph.D., and Lawrence Fong, M.D.

RAPT Therapeutics (RAPT) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

RAPT Therapeutics (RAPT) Catches Eye: Stock Jumps 6.1%

SOUTH SAN FRANCISCO, Calif., Sept.  03, 2020  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present a corporate update and company overview at the following conferences:

RAPT Therapeutics to Present at Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug.  13, 2020  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent operational and business progress.

RAPT Therapeutics Reports Second Quarter 2020 Financial Results

As of late, it has definitely been a great time to be an investor in RAPT Therapeutics.

RAPT's Shares March Higher, Can It Continue?

SOUTH SAN FRANCISCO, Calif., June  18, 2020  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the election of Peter Svennilson, Managing Partner of The Column Group, to its Board of Directors. Mr. Svennilson will replace David Goeddel, Ph.D., who did not stand for reelection to RAPT’s Board of Directors due to other responsibilities, but will remain a member of RAPT’s Scientific Advisory Board (SAB).

Peter Svennilson Elected to RAPT Therapeutics Board of Directors

SOUTH SAN FRANCISCO, Calif., June  17, 2020  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present a corporate update and company overview at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23rd at 11:30 a.m. Eastern Time.

RAPT Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May  29, 2020  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the presentation of a Trials in Progress poster for the ongoing seamless Phase 1/2 clinical trial of FLX475, a small molecule CCR4 antagonist in development for multiple tumor types. The poster was presented at the American Society of Clinical Oncology (ASCO) 2020.

RAPT Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Virtual Scientific Program

Preclinical and Healthy Volunteer Data Show Promise of RPT193 to Block Th2 Cells in Allergic Inflammatory Disease Preclinical and Healthy Volunteer Data Show Promise of RPT193 to Block Th2 Cells in Allergic Inflammatory Disease

RAPT Therapeutics Highlights Early Results for RPT193 at Society for Investigative Dermatology Meeting

SOUTH SAN FRANCISCO, Calif., May  14, 2020  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2020 and provided an update on recent operational and business progress.

RAPT Therapeutics Reports First Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., March  04, 2020  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the promotions of Paul Kassner, Ph.D., to Senior Vice President of Quantitative and Computational Biology and Lisa Moore, Ph.D., to Vice President of Business Development and Strategy.

RAPT Therapeutics Announces Management Promotions

SOUTH SAN FRANCISCO, Calif., Feb.  07, 2020  (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its underwritten public offering of 2,500,000 shares of common stock at a public offering price of $30.00 per share.

News for Rapt Therapeutics Inc Stock (RAPT)